The company said revenue for the fiscal Q2 quarter ended April 30, 2024 rose 7% year over year to $942.6 million. CooperVision revenue increased 8% to $635.9 million, and CooperSurgical revenue increased 6% to $306.7 million.

1. 01

   The company said revenue for the fiscal Q2 quarter ended April 30, 2024 rose 7% year over year to $942.6 million. CooperVision revenue increased 8% to $635.9 million, and CooperSurgical revenue increased 6% to $306.7 million.

2. 02

   The company said GAAP diluted earnings per share for Q2 were $0.44, up $0.24 from a year earlier, and non-GAAP diluted earnings per share were $0.85, up $0.08. GAAP net income was $88.9 million, and the GAAP operating margin was 17%.

3. 03

   The company said free cash flow for Q2 was $36.9 million, calculated as operating cash flow of $111.0 million less capital expenditures of $74.1 million. Total debt excluding unamortized debt issuance costs was $2.7 billion, and cash and cash equivalents were $112.4 million.

4. 04

   The company raised its fiscal 2024 outlook, setting total revenue guidance at $3,863 to $3,905 million (organic growth of 7.5% to 8.5%) and non-GAAP diluted earnings per share guidance at $3.54 to $3.60, the company said.

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.